Europe Gastrointestinal Drugs Market Trends and Analysis by 2027

The Europe gastrointestinal drugs market is expected to reach US$ 17,810.81 million by 2027 from US$ 12,721.85 million in 2019; it is estimated to grow at a CAGR of 4.4% from 2020 to 2027.

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

The European Medicines Agency approved the first biosimilar therapies in 2006. Europe has the largest number of approved biosimilar medicines owing to high biologic costs and demand for cheaper medicines. For example, several adalimumab biosimilars were launched in 2019 in Europe. Europe has witnessed a smooth transition toward the use of biosimilars owing to its well-established regulatory framework. However, due to lack of regulation, there are very few approved biosimilars in gastroenterology with more in the pipeline. In January 2016, 22 biosimilars have been approved by the European Medicines Agency. The first biosimilars for inflammatory bowel disease (IBD) in the European Union were registered in 2013, and the first use of biosimilars of infliximab (reference product Remicade, Janssen) began around the spring and summer of 2014. The approval of a biosimilar in GI disorders is expected to increase in the coming years.

For instance, In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis.  Moreover, despite regulatory hurdles for the biosimilar market, it is still projected to grow at a rapid rate due to the need for cheaper alternatives to biologics. High costs associated with the manufacturing of biologic medicines have made biosimilar an attractive option for drug manufacturers, providing a platform for further growth.

The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Short-term impacts of COVID-19 pandemic includes demand changes, revision in regulatory process, changes in research and development process and the shift towards tele-communication and tele-medicine. But the growing awareness about gastrointestinal products available in market in Europe during is likely to demand for constipation drug products and supply in COVID-19 Pandemic, hence it can boost the growth of the gastrointestinal drugs market

Rest of Europe Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE GASTROINTESTINAL DRUGS MARKET SEGMENTATION

By Drug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Anti-Inflammatory Drugs
• Antiemetic and Antinauseants
• Biologics
• Others

By Route of Administration

• Oral
• Parenteral

By Application

• Inflammatory Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome
• Gastroenteritis
• Celiac Disease
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Johnson and Johnson Services, Inc.
• Sanofi
• GlaxoSmithKline plc.
• AstraZeneca
• Bayer AG

Europe Gastrointestinal Drugs Report Scope